ITANET Registry for Collecting Data on Gastro-Enteric-Pancreatic Neuroendocrine Tumors in Italy
Led by Italian Association Neuroendocrine Tumors · Updated on 2024-01-25
3600
Participants Needed
37
Research Sites
261 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are collecting data to create an Italian database focused on gastro-entero-pancreatic neuroendocrine tumors GEP-NET. This observational study aims to gather information on how these tumors are diagnosed, treated, and monitored over time. The study continues previous efforts from an international database, ensuring important clinical details are not lost for patients in Italy.
Participants data will be entered into a secured online database managed by the Italian Association Neuroendocrine Tumors ITANET. The data collection includes new diagnoses and follow-up visits, with retrospective data allowed for patients diagnosed within one year before consenting. Follow-up visits and treatments are based on individual patient needs, and data accuracy is carefully checked and validated by ITANET.
During the study, patients will undergo regular clinical visits as part of their usual care. The data collected will include tumor classification, diagnostic tools used, treatment methods such as surgery or medication, and disease progression. The study tracks important outcomes like tumor incidence, location, diagnosis timing, and treatment types over a three-year period, with ongoing data updates planned annually.
CONDITIONS
Brief Title
Protocol ITANET - Registry
Research Team
F
Francesco Panzuto
M
Maria Rinzivillo
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Confirmed diagnosis of neuroendocrine tumor by biopsy or supported by PET Gallium 68 and advanced imaging (CT scan or MRI)
Diagnosis of GEP-NET within 1 year before signing informed consent
Tumor grading G1, G2, or G3 according to WHO 2019 classification
Tumor originates in the digestive system or has unknown origin
Signed informed consent
You will not qualify if you...
Tumor origin known to be outside the digestive system
No confirmed diagnosis of neuroendocrine tumor by biopsy or supported imaging
Diagnosis of GEP-NET made more than 1 year before signing informed consent
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) during outpatient visit or hospitalization
Surveillance
Duration - Up to 3 years
Participants who undergo routine care are observed with data collected yearly to monitor disease progression and management.
Yearly visits as part of clinical follow-up
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database.
Francesco Panzuto, Stefano Partelli, Davide Campana...